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Abstract
Background: Glycogen storage disease type 0 is an autosomal recessive disease presenting in infancy or early
childhood and characterized by ketotic hypoglycemia after prolonged fasting and postprandial hyperglycemia and
hyperlactatemia. Sixteen different mutations have been identified to date in the gene which encodes hepatic
glycogen synthase, resulting in reduction of glycogen storage in the liver.
Case Presentation: Biochemical evaluation as well as direct sequencing of exons and exon-intron boundary
regions of the GYS2 gene were performed in a patient presenting fasting hypoglycemia and postprandial
hyperglycemia and her parents. The patient was found to be compound heterozygous for one previously reported
nonsense mutation (c.736 C>T; R243X) and a novel frameshift mutation (966_967delGA/insC) which introduces a
stop codon 21 aminoacids downstream from the site of the mutation that presumably leads to loss of 51% of the
COOH-terminal part of the protein. The glycemia and lactatemia of the parents after an oral glucose tolerance test
were evaluated to investigate a possible impact of the carrier status on the metabolic profile. The mother, who
presented a positive family history of type 2 diabetes, was classified as glucose intolerant and the father, who did
not exhibit metabolic changes after the glucose overload, had an antecedent history of hypoglycemia after
moderate alcohol ingestion.
Conclusion: The current results expand the spectrum of known mutations in GYS2 and suggest that
haploinsufficiency could explain metabolic abnormalities in heterozygous carriers in presence of predisposing
conditions.
Background
Glycogen storage disease type 0 (GSD0) is an autosomal
recessive disease presenting in infancy or early child-
hood caused by mutations in the GYS2 [1], a gene
located on chromosome 12p 12.2 composed of 16 exons
which codes for the hepatic isoform of glycogen
synthase (GS) [2]. This rate-limiting enzyme of 80.9 kDa
participates in the production of glycogen, the glucose
polymer which constitutes the major repository of read-
ily available energy [3-5].
Glucose use is strictly controlled and abnormal glu-
cose handling is associated with some human diseases,
such as glycogen storage diseases [3] and diabetes [6].
GS is a key component of the hepatic synthesis of glyco-
gen, catalyzing the successive addition of a-1,4-linked
glucose residues to the nonreducing end of glycogen [4].
Impaired activity of GS results in great reduction of gly-
cogen storage in the liver, which renders the patient
prone to develop ketotic hypoglycemia and low lactate-
mia after prolonged fasting. The inability to synthesize
hepatic glycogen shifts meal-derived glucose from glyco-
genesis to the glycolytic pathway and explains the find-
ings of hyperglycemia, hyperlactatemia and
hyperlipidemia in the postprandial period [7-9].
The current gold standard for diagnosis is molecular
analysis of the affected gene, which replaced liver biopsy
[7]. Sixteen different mutations have been identified to
date [1,7,8,10]. In the present report, we describe a
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novel deletion insertion mutation in the GYS2 gene in a
Brazilian child as well as the glycemia and lactatemia of
her parents after an oral glucose tolerance test, to inves-
tigate a possible impact of the carrier status on the
metabolic response to glucose overload.
Case Presentation
This third female child of healthy nonconsanguineous
parents was born at full term without complications
weighting 3.050 g and had normal psychomotor devel-
opment. At 6 months of age she developed sweating
during fast, mainly in the mornings. At 2 years measure-
ments of capillary glycemia revealed fasting hypoglyce-
mia (1.94 mmol/L) with ketonemia and postprandial
hyperglycemia (11.3 mmol/L). At 6 years of age, the
patient was evaluated at the Endocrinology Department
of Hospital das Clinicas for diagnosis confirmation. Her
physical examination was normal, without hepatomegaly
or neurological abnormalities. Her weight and height
were in the 25th and 10-25th percentiles, respectively.
Her HbA1c was 5.2%.
None of the patient’s first-degree relatives had a posi-
tive history of hypoglycemic episodes during fasting
however the father presented some episodes of hypogly-
cemia after moderate alcohol ingestion (5 to 7 ethanol
doses, approximately 90 grams of ethanol) during ado-
lescence. In two occasions, he was taken to the hospital
and had documented hypoglycemia (capillary blood glu-
cose concentrations between 2.5 and 2.7 mmol/L) and
improvement of the symptoms after glucose infusion.
The mother presented a positive family history of type 2
diabetes, a BMI of 24.3 kg/m2, an HbA1c of 6.3%, a
basal insulinemia of 5.6 μU/mL and a Homeostatic
Model Assessment (HOMA)-IR of 1.08.
The biochemical investigation was carried out as fol-
lows: hourly measurements of plasma glucose, ketones,
insulin, C-peptide and blood lactate concentrations were
performed during fasting. After the plasma glucose con-
centration decreased to < 2.7 mmol/L, glucagon (0.03
mg/kg) was administered intravenously, and plasma glu-
cose and blood lactate concentrations were measured at
30 and 60 minutes. Thereafter, the patient had a mixed
meal with measurements of plasma glucose and blood
lactate every 30 minutes for 3 hours as previously
described by Bachrach and Weinstein [7,8]
Cortisol, insulin, C-peptide were measured by a
immunofluorimetric assay (Wallac AutoDELFIA, Turku,
Finland), ACTH and IGF-1 were measured by a immu-
nometric assay (DPC Immulite, Los Angeles, USA). The
plasma glucose and blood lactate were measured by the
enzymatic method.
Following written consent, which was obtained from
the patient’s parents for publication of study, blood sam-
ples were collected from the proband and her parents
for mutation screening. Polymerase chain reaction
(PCR) and direct sequencing of exons and exon-intron
boundary regions of the GYS2 gene was performed as
previously described [1] in genomic DNA.
Plasma glucose and blood lactate concentrations were
obtained from the parents before and every 30 minutes
for 2 hours after a 75-g oral glucose tolerance test
(OGTT). The study was carried out in compliance to
the Institution’s Ethics Committee and in accordance to
The Declaration of Helsinki, with informed and free
consent being required of each subject or subject’s
guardian.
Ketotic hypoinsulinemic hypoglycemia and absence of
hormonal deficiencies were demonstrated after a 5-hour
fast (Table 1). Glucagon infusion did not promote a nor-
mal glycemic response, and a mixed meal resulted in
postprandial hyperglycemia and hyperlactatemia (Table
2). Direct sequencing of the coding region of the GYS2
gene revealed that the affect child was compound het-
erozygous for two mutations: a novel mutation resulting
from deletion/insertion (966_967delGA/insC at codons
322/323 in exon 7) resulting in overlapping peaks begin-
ning at nucleotide c.966 (filled arrow) and a previously
described nonsense mutation which causes the substitu-
tion of an arginine (CGA) for a stop codon (TGA)
(c.736 C>T at codon 246 in exon 5; R246X) [1] (Figure
1). The 966_967delGA/insC mutation results in a frame-
shift of the reading frame from codon 323, leading to a
premature stop codon (codon 343). Genetic analysis of
the parents demonstrated that the mother was carrier of
the mutation c.736 C>T and the father was carrier of
the mutation 966_967 delGAinsC (Table 3).
As shown on Table 3, the parents did not present
hypoglycemia after a 12-hour fasting period and the
mother was classified as glucose intolerant.
Patient was recommended to start a diet enriched in
proteins and in low glycemic carbohydrates, especially
cornstarch (1-1.5 g/kg), after which the hypoglycemic
episodes became less frequent and less intense.
The present study reports the identification of a novel
deletion/insertion mutation in the GYS2 gene in a
patient with GSD0. As far as we know, this is the 17th
different mutation described thus far [7,8,10], the first in
Table 1 Metabolic and hormonal response to fasting (5
hours)
Glycemia (3,33-6,05 mmol/L) 1,16
Insulinemia (< 173 pmol/L) < 15
C-Peptide (0.13-1,2 nmol/L) < 0.15
Ketonemia (< 0.5 mmol/L) 4.7
IGF-1 (2,62-22,3 nmol/L) 4,45
ACTH (<13,2 pmol/L) 7,48
Cortisol (193-855 nmol/L) 549
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a Brazilian patient. The mutations T445M in exon 11
[7,10] and R246X in exon 5 [1,8] were found in more
than one family, including the family reported here,
which has European ancestry and harbors the latter
nonsense mutation. On the second allele, our patient
was found to have a new frameshift mutation comprised
of a 2 bp deletion and a 1 bp insertion which introduced
a stop codon 21 aminoacids downstream from the site
of the mutation (aminoacid 343) that presumably leads
to loss of 51% of the COOH-terminal part of the pro-
tein, including potential phosphorylation sites as well as
a highly conserved region believed to contain the glu-
cose-6-P binding site (aminoacids 501-600) [11]. This
predicted loss could result in impaired or null GS activ-
ity, which is known to be regulated by binding allosteric
ligands, most notably glucose-6-P, and by covalent phos-
phorylation [3].
The mutations described so far seem to point out the
absence of genotype-phenotype correlation, as
Table 2 Response of plasma glucose, lactate and insulin











After 5 h Fast
0 3,21 3,77 -
60 2,66 1,99 -
150 2,27 1,55 -
300 1,98 1,33 < 17
361 Glucagon Infusion EV
390 3,13 1,76 -
420 1,83 1,65 < 17
Mixed Meal
60 11,32 5,77 316,4
90 9,26 6,54 332,4
120 10,21 7,54 259,5
150 7,1 6,98 197,8
Table 3 First-degree relatives' genetic analysis and response of plasma glucose and lactate to fasting and oGTT
Basal* 30 min 60 min 120 min Genetic
Mother Glycemia 4,88 7,82 9,43 7,99 Heterozygote for c.736 C >T (R246X)
(31 years) Lactate 0,44 0,75 1,15 1,06
Ketonemia 0,8
Father Glycemia 4,71 7,15 5,88 4,21 Heterozygote for 966_967 delGAinsC
(33 years) Lactate 0,65 1,64 0,93 1,95
Ketonemia 1,2
* 12-h fasting; oGTT: oral glucose tolerance test with 75 g glucose
Figure 1 Sequencing electropherograms showing GYS2 mutations. A: Sequencing electropherograms showing the substitution of C to T at
nucleotide 736 resulting in a stop codon at exon 5 (c.736 C>T; R243X) (Upper panel) and the exon 7 deletion (GA) plus insertion (C) mutation at
nucleotides 966-967 (966_967delGA/insC) also resulting in a premature stop codon (bottom panel). B: Frameshift in the codon sequence which
is predicted to result in truncation of the GYS2 protein at amino acid 343.
Soggia et al. BMC Medical Genetics 2010, 11:3
http://www.biomedcentral.com/1471-2350/11/3
Page 3 of 5
exemplified by mutation R246X, which leads to loss of
65% of the COOH-terminal part of the protein and total
lack of GS activity demonstrated by a functional study
[1]. Orho et al reported a homozygous patient for this
mutation presenting practically normal hepatic glycogen.
Besides, absence of fasting hypoglycemia and postpran-
dial hyperglycemia were documented in heterozygous
carriers of this mutation [1]. In the presently studied
family, the mother was carrier of the R246X mutation
and did not develop fasting hypoglycemia however she
presented glucose intolerance in the OGTT. Based on
the finding of fasting hypoglycemia in one heterozygous
carrier of a mutation in the 5’-donor splicing site of
intron 6, that predictably results in skipping of exon 6
and a premature stop codon in exon 7, Orho et al. [1]
proposed that this truncated protein might disturb the
structure of the wild-type GS, which is believed to be a
dimer [3] acting in a dominant-negative manner.
An alternative possibility for the finding of metabolic
abnormalities in some heterozygous carriers could be hap-
loinsufficiency in the presence of other predisposing con-
ditions, in a mechanism similar to the one proposed to
explain how abnormal gene dosage is associated with
human birth defects: increased sensitivity to effects of
environmental insults [12]. In the family presented herein,
both parents presented predisposing conditions to meta-
bolic abnormalities: the mother, classified as glucose intol-
erant, have a positive family history of type 2 diabetes and
the father presented episodes of hypoglycemia after mod-
erate alcohol ingestion. Alcohol is known to inhibit gluco-
neogenesis and is therefore more likely to contribute to
the development of hypoglycemia when glycogen stores
are low [13]. The absence of hyperlactatemia after glucose
overload in both parents could speak against the hypoth-
esis of haploinsufficiency however this biochemical feature
may be absent even in patients with GSD0 [7].
The present data are insufficient to draw any conclu-
sion regarding the susceptibility of heterozygous carriers
of GYS2 mutations to glucose metabolism abnormalities,
especially because a previous linkage study did not iden-
tify this as a major gene contributing to type 2 diabetes
susceptibility [14]. However, they may suggest that in
presence of predisposing conditions, carriers of GYS2
mutations might be at increased risk of developing
hypoglycemia.
Conclusions
The current results expand the spectrum of known
mutations in GYS2 and suggest that haploinsufficiency
could explain metabolic abnormalities in heterozygous
carriers in presence of predisposing conditions.
Abbreviations
(GSD0): Glycogen storage disease type 0; (GS): glycogen synthase; (PCR):
polymerase chain reaction; (OGTT): oral glucose tolerance test.
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